Larionov Alexey A
Department of Medical Genetics, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
Front Oncol. 2018 Apr 3;8:89. doi: 10.3389/fonc.2018.00089. eCollection 2018.
The median survival of patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) has more than doubled, since the discovery of HER2-targeted treatments: it rose from less than 2 years in 2001 (prior introduction of trastuzumab) to more than 4 years in 2017. The initial generation of HER2-targeted therapies included trastuzumab with taxanes in the first line, followed by the addition of lapatinib and by a switch to another cytotoxic agent after progression. Results of CLEOPATRA, EMILIA, and TH3RESA trials have changed this clinical practice. The current consensus includes horizontal dual blockade (trastuzumab + pertuzumab) with taxanes or vinorelbine in the first line, followed by trastuzumab-emtansine (T-DM1) in the second line, with addition of lapatinib in the later lines of treatment. However, the fast and simultaneous development of new drugs led to a relative shortage of clinical evidence to support this sequence. Triple-positive breast cancers (TPBC), which express both hormonal receptors and HER2, constitute nearly half of HER2-positive cases. For these tumors, the current consensus is to add endocrine therapy after completion of cytotoxic treatment. Again, this consensus is not fully evidence-based. In view of the recent progress in treatment of estrogen-receptor positive breast cancers, a series of trials is evaluating addition of CDK4/6 inhibitors, aromatase inhibitors or fulvestrant to HER2-targeted and cytotoxic chemotherapy in TPBC patients. Despite the remarkable progress in treatment of HER2-positive breast cancer, metastatic disease is still incurable in the majority of patients. A wide range of novel therapies are under development to prevent and overcome resistance to current HER2-targeted agents. This review discusses pivotal clinical trials that have shaped current clinical practices, the current consensus recommendations, and the new experimental treatments in metastatic HER2-positive breast cancer.
自发现针对人表皮生长因子受体2(HER2)的治疗方法以来,HER2阳性转移性乳腺癌(MBC)患者的中位生存期增加了一倍多:从2001年(曲妥珠单抗引入之前)的不到2年升至2017年的4年以上。第一代HER2靶向疗法包括一线使用曲妥珠单抗联合紫杉烷类药物,随后添加拉帕替尼,并在疾病进展后换用另一种细胞毒性药物。CLEOPATRA、EMILIA和TH3RESA试验的结果改变了这一临床实践。目前的共识包括一线使用曲妥珠单抗联合帕妥珠单抗与紫杉烷类药物或长春瑞滨进行横向双重阻断,二线使用曲妥珠单抗- 恩美曲妥珠单抗(T-DM1),并在后续治疗线中添加拉帕替尼。然而,新药的快速同步研发导致支持这一治疗顺序的临床证据相对不足。同时表达激素受体和HER2的三阳性乳腺癌(TPBC)占HER2阳性病例的近一半。对于这些肿瘤,目前的共识是在细胞毒性治疗完成后添加内分泌治疗。同样,这一共识并非完全基于证据。鉴于雌激素受体阳性乳腺癌治疗的最新进展,一系列试验正在评估在TPBC患者的HER2靶向和细胞毒性化疗中添加CDK4/6抑制剂、芳香化酶抑制剂或氟维司群。尽管HER2阳性乳腺癌的治疗取得了显著进展,但大多数患者的转移性疾病仍然无法治愈。正在开发多种新型疗法以预防和克服对当前HER2靶向药物的耐药性。本综述讨论了塑造当前临床实践的关键临床试验、当前的共识建议以及转移性HER2阳性乳腺癌的新实验性治疗方法。